Targeting GSK-3: a promising approach for cancer therapy?

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR: Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim. Biophys. Acta.1114(2–3), 147–162 (1992).
  Google Scholar
• 2  Doble BW, Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci.116(Pt 7), 1175–1186 (2003).••  Review article outlining the current understanding of the role of glycogen synthase kinase (GSK)-3 in numerous signaling pathways and human pathology.
  Medline CASGoogle Scholar
• 3  Brion JP, Anderton BH, Authelet M et al.: Neurofibrillary tangles and tau phosphorylation. Biochem. Soc. Symp.67, 81–88 (2001).
  Medline CASGoogle Scholar
• 4  Kaidanovich O, Eldar-Finkelman H: The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Exp. Opin. Ther. Targets6(5), 555–561 (2002)
  MedlineGoogle Scholar
• 5  Parker PJ, Caudwell FB, Cohen P: Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur. J. Biochem.130(1), 227–234 (1983).
  Medline CASGoogle Scholar
• 6  Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nature Immunol.6(8), 777–784 (2005).
  Medline CASGoogle Scholar
• 7  Dugo L, Collin M, Allen DA et al.: GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med. 33(9), 1903–1912 (2005).
  Medline CASGoogle Scholar
• 8  Polakis P: Wnt signaling and cancer. Genes Dev.14, 1837–1851 (2000).
  MedlineGoogle Scholar
• 9  Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature406, 86–90 (2000).••  Initial report demonstrating that ablation of GSK-3β results in embryonic lethality due to tumor necrosis factor (TNF)-α-dependent hepatocyte apoptosis, a phenotype similar to that of mice lacking the p65 nuclear factor (NF)κB subunit or Iκkinaseβ. This study pointed to an unexpected role for GSK-3β in NFκB nuclear activity.
  Medline CASGoogle Scholar
• 10  Ding VW, Chen RH, McCormick F: Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem.275, 32475–32481 (2000).
  Google Scholar
• 11  Patel S, Doble B, Woodgett JR: Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword? Biochem. Soc. Trans.32(Pt 5), 803–808 (2004).
  Medline CASGoogle Scholar
• 12  Altomare DA, Testa JR: Perturbations of the Akt signaling pathway in human cancer. Oncogene24, 7455–7464 (2005).
  Medline CASGoogle Scholar
• 13  Cheng JQ, Ruggeri B, Klein WM et al.: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA93(8), 3636–3641 (1996).
  Medline CASGoogle Scholar
• 14  Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD: Glycogen synthase kinase-3β participates in nuclear factor-κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res.65, 2076–2081 (2005).••  Initial report showing that pharmacological inhibition of GSK-3 or genetic depletion of GSK-3β decreases NFκB-mediated pancreatic cancer cell proliferation and survival. This study suggests GSK-3β as a potential therapeutic target in the treatment of pancreatic cancer.
  Medline CASGoogle Scholar
• 15  Shakoori A, Ougolkov A, Yu ZW et al.: Deregulated GSK3β activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun.334, 1365–1374 (2005).•  Suggests GSK-3β as a potential therapeutic target in colorectal cancer. Levels of GSK-3β and the two phosphorylated forms were analyzed by Western blotting in pairs of normal and tumor tissues of colorectal cancer patients (n = 20 cases). The level of GSK-3β in the tumors was higher than in their normal counterparts in 18 out of 20 cases. Inactive phospho-GSK-3β Ser9 was detected in high levels in non-neoplastic tissue in 17 out of 20 cases, whereas tumors in most cases contained only trace amounts or no detectable level of this form. Moreover, this study demonstrates that inhibition of GSK-3 or genetic depletion of GSK-3β by RNA interference induces apoptosis and attenuates proliferation of colon cancer cells.
  Medline CASGoogle Scholar
• 16  Ryves WJ, Harwood AJ: The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle. Prog. Cell Cycle Res. 5, 489–495 (2003).
  MedlineGoogle Scholar
• 17  Gould TD, Gray NA, Manji HK: Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol. Res.48(1), 49–53 (2003).
  Medline CASGoogle Scholar
• 18  Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B: Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol.15(1), 32–36 (1998).
  Medline CASGoogle Scholar
• 19  Erdal E, Ozturk N, Cagatay T, Eksioglu-Demiralp E, Ozturk M: Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int. J. Cancer115(6), 903–910 (2005).
  Medline CASGoogle Scholar
• 20  Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS: Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood93(9), 3044–3052 (1999).
  Medline CASGoogle Scholar
• 21  Griffin JD: Leukemia stem cells and constitutive activation of NF-κB. Blood98(8), 2291 (2001).
  Google Scholar
• 22  Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C: Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia14(3), 399–402 (2000).
  Medline CASGoogle Scholar
• 23  Baron F, Turhan AG, Giron-Michel J et al.: Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 99(6), 2107–2113 (2002).
  Medline CASGoogle Scholar
• 24  Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD: Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene18(51), 7389–7394 (1999).
  Medline CASGoogle Scholar
• 25  Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr: Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol.17(7), 3629–3639 (1997).
  Medline CASGoogle Scholar
• 26  Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ: The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res.5, 119–127 (1999).
  Medline CASGoogle Scholar
• 27  Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science274(5288), 782–784 (1996).
  Medline CASGoogle Scholar
• 28  Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med. 5(4), 412–417 (1999).
  MedlineGoogle Scholar
• 29  Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene18, 6853–6866 (1999).
  Medline CASGoogle Scholar
• 30  Andela VB, Schwarz EM, Puzas JE, O’Keefe RJ, Rosier RN: Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kB. Cancer Res.60, 6557–6562 (2000).
  Medline CASGoogle Scholar
• 31  Aggarwal BB: Nuclear factor-kB: the enemy within. Cancer Cell6(3), 203–208 (2004).••  Review article, outlining the role of NFκB activation in human cancer suggesting inhibition of NFκB as an effective method in the prevention and treatment of cancer.
  Medline CASGoogle Scholar
• 32  Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature376(6536), 167–170 (1995).
  Medline CASGoogle Scholar
• 33  Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM: Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science284(5412), 321–325 (1999).
  Medline CASGoogle Scholar
• 34  Beyaert R, Vanhaesebroeck B, Suffys P, Van Roy F, Fiers W: Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc. Natl Acad. Sci. USA86(23), 9494–9498 (1989).
  Medline CASGoogle Scholar
• 35  Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM: Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene23(47), 7882–7892 (2004).•  Shows that inhibition of GSK-3 leads to a reduction both in androgen receptor (AR) protein levels and the growth of AR-positive prostate cancer cell lines, suggesting a novel therapeutic application for GSK-3 inhibitors in prostate cancer.
  Medline CASGoogle Scholar
• 36  Liao X, Zhang L, Thrasher JB, Du J, Li B: Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol. Cancer Ther.2(11), 1215–1222 (2003).
  Medline CASGoogle Scholar
• 37  Ghosh JC, Altieri DC: Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3β in colorectal cancer cells. Clin. Cancer Res.11(12), 4580–4588 (2005).
  Medline CASGoogle Scholar
• 38  Collett GP, Campbell FC: Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis25(11), 2183–2189 (2004).
  Medline CASGoogle Scholar
• 39  Thisse C, Perrin-Schmitt F, Stoetzel C, Thisse B: Sequence-specific transactivation of the Drosophilatwist gene by the dorsal gene product. Cell65(7), 1191–1201 (1991).
  Medline CASGoogle Scholar
• 40  Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I: p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell1(5), 493–503 (2002).
  Medline CASGoogle Scholar
• 41  Deng J, Xia W, Miller SA, Wen Y, Wang HY, Hung MC: Crossregulation of NF-kappaB by the APC/GSK-3β/β-catenin pathway. Mol. Carcinog.39(3), 139–146 (2004).
  Medline CASGoogle Scholar
• 42  Deng J, Miller SA, Wang HY et al.: β-catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell2(4), 323–334 (2002).
  Medline CASGoogle Scholar
• 43  Steinbrecher KA, Wilson W 3rd, Cogswell PC, Baldwin AS: Glycogen synthase kinase 3[β] functions to specify gene-specific, NF-[κ]B-dependent transcription. Mol. Cell Biol.25(19), 8444–8455 (2005).••  Identifies a subset of NFκB-regulated genes that require GSK-3β for efficient expression and demonstrates that GSK-3β has a profound effect on NFκB transcription in a gene-specific manner through a mechanism involving control of promoter-specific recruitment of NFκB.
  Medline CASGoogle Scholar
• 44  Schwabe RF, Brenner DA: Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol.283(1), G204–G211 (2002).
  MedlineGoogle Scholar
• 45  Buss H, Dorrie A, Schmitz ML et al.: Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J. Biol. Chem.279(48). 49571–49574 (2004).
  Medline CASGoogle Scholar
• 46  Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM: Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J. Cell. Biol.168(1), 29–33 (2005).
  Medline CASGoogle Scholar
• 47  Warburg O: The metabolism of tumors. Constable Press, London (1930).
  Google Scholar
• 48  Warburg O: On the origin of cancer cells. Science123, 309–314 (1956).
  Medline CASGoogle Scholar
• 49  Garber K: Energy boost: The Warburg effect returns in a new theory of cancer. J. Natl Cancer Inst.96, 1805–1806 (2004).
  MedlineGoogle Scholar
• 50  Gatenby RA, Gawlinski ET: The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res.63, 3847–3854 (2003).••  Describes the benefits of anaerobic glycolysis for cancer cells in terms of tumor invasion, increased proliferation and vascularization in a tumor–host interaction model.
  Medline CASGoogle Scholar
• 51  Namiot Z, Stasiewicz J, Szalaj W, Skwarski L, Jodczyk J, Gorski J: Gastric cancer with special references to WHO and Lauren's classifications: glycogen and triacylglycerol concentrations in the tumor. Neoplasma36, 363–368 (1989).
  Medline CASGoogle Scholar
• 52  Takahashi S, Satomi A, Yano K et al.: Estimation of glycogen levels in human colorectal cancer tissue: relationship with cell cycle and tumor outgrowth. J. Gastroenterol.34, 474–480 (1999).
  Medline CASGoogle Scholar
• 53  Rask K, Nilsson A, Brannstrom M et al.: Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β. Br. J. Cancer 89(7), 1298–1304 (2003).•  Expression of GSK-3β was analyzed by Western blotting and statistical analysis, revealing significant increase in GSK-3β (p < 0.001) expression in the group of ovarian adenocarcinomas compared with the group of normal ovaries and benign adenomas/borderline tumors.
  Medline CASGoogle Scholar
• 54  Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K: Cyclin D1 overexpression correlates with β-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 β and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 24(3), 435–442 (2003).
  Medline CASGoogle Scholar
• 55  Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR: Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science275, 1930–1934 (1997).
  Medline CASGoogle Scholar
• 56  Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr: The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell8(1), 25–33 (2005).
  Medline CASGoogle Scholar
• 57  De Ketelaere A, Vermeulen L, Vialard J et al.: Involvement of GSK-3β in TWEAK-mediated NF-κB activation. FEBS Lett.566(1–3), 60–64 (2004).
  Medline CASGoogle Scholar
• 58  Senderowicz AM: Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. 2(4 Suppl. 1), S84–S95 (2003).
  MedlineGoogle Scholar
• 59  Leclerc S, Garnier M, Hoessel R et al.: Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem.276(1), 251–260 (2001).••  Describes most cyclin-dependent kinase inhibitors as powerful GSK-3 inhibitors and raises the question of dual-specificity effect of these drugs in the treatment of human cancer.
  Medline CASGoogle Scholar
• 60  Kim DM, Koo SY, Jeon K et al.: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res.63(3), 621–626 (2003).
  Medline CASGoogle Scholar
• 61  Kitada S, Zapata JM, Andreeff M, Reed JC: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96(2), 393–397 (2000).
  Medline CASGoogle Scholar
• 62  Wittmann S, Bali P, Donapaty S et al.: Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res.63(1), 93–99 (2003).
  Medline CASGoogle Scholar
• 63  Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J. Clin. Oncol.16(3), 1207–1217 (1998).
  Medline CASGoogle Scholar
• 64  Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R, Zhivotovsky B: Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene21(1), 65–77 (2002).
  Medline CASGoogle Scholar